{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T15:28:28Z","timestamp":1724340508700},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We report a case of a 59-year-old man with prostate adenocarcinoma, Gleason score 9 after prostatectomy and adjuvant radiotherapy. The patient showed biochemical recurrence. On standard <jats:sup>68<\/jats:sup>Ga-PSMA PET\/CT examination, 60 minutes postinjection, the PET\/CT images showed only trace accumulation in the ureters. To identify lesions close to the ureters, imaging of the pelvis was performed 2 hours postinjection. The delayed image showed clearly visible increased uptake in a right internal iliac lymph node that was normal-sized by CT. The patient underwent radiotherapy with planning based on the <jats:sup>68<\/jats:sup>Ga-PSMA PET\/CT image. Follow-up testing showed prostate-specific antigen level reduction to 0.04 ng\/mL.<\/jats:p>","DOI":"10.1097\/rlu.0000000000002966","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T20:17:59Z","timestamp":1581538679000},"page":"e213-e214","source":"Crossref","is-referenced-by-count":5,"title":["68Ga-PSMA PET\/CT in Recurrence Prostate Cancer. Should We Perform Delayed Image in Cases of Negative 60 Minutes Postinjection Examination?"],"prefix":"10.1097","volume":"45","author":[{"given":"Jolanta","family":"Kunikowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szymon","family":"Kujda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leszek","family":"Kr\u00f3licki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"e696","DOI":"10.1016\/S1470-2045(18)30604-1","article-title":"Consensus on molecular imaging and theranostics in prostate cancer","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00259-018-4189-7","article-title":"68Ga-PSMA-11 PET\/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/RLU.0000000000002169","article-title":"68Ga-PSMA PET\/CT in patients with biochemical recurrence of prostate cancer: a prospective, 2-center study","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","article-title":"68Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions","volume":"40","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1007\/s00259-017-3669-5","article-title":"Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET\/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00259-018-3970-y","article-title":"Optimal time-point for 68Ga-PSMA-11 PET\/CT imaging in assessment of prostate cancer: feasibility of sterile cold-kit tracer preparation?","volume":"45","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002966","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:03:28Z","timestamp":1695621808000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002966","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,12]]}}}